Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho Securities Remains Sidelined Following Endo Int'l's (ENDP) Mixed 4Q Results
March 2, 2016 7:10 AM ESTMizuho Securities reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $42.00 (from $55.00), following the company's 4Q earnings report. ENDP reported revenues of $1.07B, in-line with consensus' estimate. EPS was reported at $1.36, ahead of expectations of $1.27. ENDP introduced... More
Piper Jaffray Remains Bullish on Endo Int'l (ENDP) Following an In-Line 4Q - PT to $81
March 1, 2016 9:04 AM ESTPiper Jaffray maintained an Overweight rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $81.00 (from $83.00), following the company's relatively in-line 4Q earnings results. Endo reported 4Q15 non-GAAP EPS of $1.36 on revenues of $1.1B. Sales of Xiaflex in 4Q15 were $50M, up 26% versus 3Q15 sales of $40M, with ENDP citing... More
Leerink Partners Cuts Price Target on Endo Int'l (ENDP) Following 4Q Earnings Report
March 1, 2016 7:50 AM ESTLeerink Partners maintained an Outperform rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $51.00 (from $64.00), following the company's 4Q earnings report. ENDP generics were unfavorably impacted by increased pricing pressure in pain and commodity products within legacy Qualitest, an... More
